VNA
CSTL icon

Valley National Advisers’s Castle Biosciences CSTL Stock Holding History

Valley National Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-85
Closed -$1K – 839
2024
Q2 		$1K Hold
85
– – ﹤0.01% 1019
2024
Q1 		$1K Buy
85
+20
+31% +$435 ﹤0.01% 1054
2023
Q4 		$1K Buy
+65
New +$1.14K ﹤0.01% 1048

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Valley National Advisers's CSTL Position: Q3 2024 in Review

Valley National Advisers sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 85 shares — an estimated $1K sold.

Valley National Advisers first reported a position in CSTL in Q4 2023 and held it in 3 quarters. The position peaked at $1K in Q2 2024. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Valley National Advisers reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Valley National Advisers sold 85 Castle Biosciences shares in Q3 2024, an estimated $1K.
  • Valley National Advisers first reported a position in Castle Biosciences in Q4 2023 and held it in 3 quarters.
  • Valley National Advisers's Castle Biosciences position peaked at $1K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Valley National Advisers's 13F filing for Q3 2024, filed 24 Oct 2024.